Proactive Investors - Run By Investors For Investors

IXICO chosen as partner for Medical Imaging & Artificial Intelligence Centre

The newly established centre brings together a consortium including London universities, NHS Trusts plus industry partners including global multinationals and UK-based SME's and the Health Innovation Network
Artificial intelligence
The centre will explore how advanced imaging and AI technologies can be used to improve medical treatment

IXICO PLC (LON:IXI) has been chosen as a small-to-medium enterprise (SME) partner in the London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare.

The data analytics company focused on delivering insights in neuroscience said the newly established centre, launched on 28 February, is part of the UK Government's Industrial Strategy Challenge Fund.

READ: IXICO gets vote of confidence from big pharma

Led by King's College London, the new Centre will develop and train sophisticated artificial intelligence algorithms from NHS medical images and patient data to provide tools for clinicians to speed up and improve diagnosis and care across a number of patient pathways including dementia, heart failure and cancer.

"We are excited to be selected to be part of this flagship UK Government initiative to ensure that UK science is at the forefront of the application and impact of artificial intelligence to the future of healthcare,” said Giulio Cerroni, the chief executive officer of IXICO.

“The development and application of artificial intelligence technology will enable IXICO to develop highly valued, innovative solutions to our biopharmaceutical clients in support of their neuroscience clinical development programmes. We are looking forward to collaborations with other leaders across this expanding field of research," he added.

View full IXI profile View Profile

IXICO PLC Timeline

Related Articles

test tubes
May 02 2019
Proactive takes a closer look at an innovative drugs company that has largely flown under the radar
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use